louisiana semaglutide side effect class action Wegovy Lawsuit Alleges Vision Loss Effects Concealed by Novo Nordisk What Gastrointestinal Side Effects Qualify

Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity

Plaintiffs belong to an employer-sponsored health benefit plan for which CVS Caremark acts as a pharmacy benefit manager (PBM)

GLP-1, or glucagon-like peptide 1, is a hormone present naturally in the body

These findings highlight the importance of targeted therapeutic strategies based on HF phenotypes

Learn how forced degradation studies identify stability risks and impurity profiles in GLP-1 peptide drugs to support regulatory and analytical confidence.